We would like to congratulate to Dr Martin-Broto on his presentation at 2022 ASCO Annual Meeting, where he presented the results of PALBOSARC (GEIS 51). Palbociclib showed signs of activity in this Phase II study on advanced STS patients (several histologic subtypes with the exception of WD/DD liposarcoma), selected based on high expression levels of CDK4. Interestingly, higher levels of CDK4 correlated with a longer PFS and OS. This was a nice example of a biomarker-guided academic clinical trial, based on preclinical evidence.
In addition, congratulations to David Moura, PhD, for the great poster defending in ASCO meeting that focused on EZH2 expression as a prognostic factor in sarcoma patients treated with nivolumab + sunitinib.